The Chemilogics™ Platform
Drug Discovery From Within
We are accessing the vast untapped chemistry encoded within the human body to efficiently identify safe, effective, oral small molecule medicines with the potential to treat nearly every disease.
Turning small molecule drug discovery inside out.
Validate. Scale. Accelerate.
Empress is advancing a new paradigm that challenges the traditional, linear – and ultimately lengthy, expensive, and risky approach – of small molecule drug development.
By shifting the drug discovery process from the traditional approach to starting with molecules that are already “human-qualified,” Empress is transforming how small molecule drugs are discovered, validated, and translated into meaningful medicines for an array of diseases for patients around the world.
We have developed a proprietary set of technologies and capabilities to identify small molecules within the human body that have a higher likelihood of succeeding as safe, potent, and effective therapies.
medicines from within
The Chemilogics™ Platform
We use vast computing power and genomic sequence data to find small molecules encoded in DNA that could be influential in human health and appropriate for drug development.
With our Chemilogics platform, we’ve identified targets and therapeutic small molecules as well as biomarkers that are important in health and disease and stratify patient populations.
Validate
Gather metagenomic data from tens of thousands of individuals worldwide
AI/ML maps biosynthetic pathways and disease linkages
Scale
Accelerate
.png)
Co-evolution has already tested countless chemistries in our bodies, over millennia, and the encoded instructions can be found in commensal DNA. By sourcing metagenomic data from patients around the world and using AI to identify, decode, and map these chemistries to health and disease, we can rapidly identify the most valuable starting points for generating new drugs.
Our platform takes in genomic data and generates small molecule drug candidates matched to therapeutic potential. We harness ever-increasing amounts of genomic data and cutting-edge and proprietary advances in AI, synthetic biology, and chemoproteomics to rapidly filter, query, and generate hundreds of drug candidates.
With the Chemilogics platform, we filter hundreds of thousands of potential chemistries to a few hundred per indication. We generate hypotheses linking specific chemistries to diseases and pathways in days, testable amounts of compounds in weeks, and in vitro and in vivo proof of concepts in months. The output is potent, selective, human-compatible small molecules that are advantaged starting points for new drugs.
Discover the power within
Developing transformative therapies, quickly, for a wide range of diseases
Identifying molecules that are already active in people provides a privileged starting point for generating new medicines.
Our Chemilogics platform puts us at the forefront of faster drug discovery.
In less than a year, Empress identified more than a dozen small molecules with proven pharmaceutical properties such as potency, specificity, and dose-dependent therapeutic activity.
Programs based on these molecules offer the potential to create new therapies to treat immune diseases as well as metabolic diseases, cancer, and neurological disorders. We plan to advance several into the clinic within the next few years.
We see an unprecedented opportunity to make small molecule drug discovery more predictable and productive, going from hypothesis to potential drug candidates in months, not years.
Our mission is to make drugs fast, and to ultimately deliver effective, safe, easy-to-use, value-driven medicines for millions of patients.
